We are a biotech spin-off developing an innovative cell therapeutic platform to create next generation cell therapies in oncology. Our products - STAb Therapeutics - have been developed based on solid discoveries from our team of scientific founders at the Hospital 12 de Octubre in Madrid. We are harnessing cell engineering techniques to develop a new wave of cell therapies capable of efficiently redirecting the immune system with our STAb Therapeutics. Our technological approach involves a T cell redirecting strategy that combines principles of adoptive cell therapy and bispecific antibodies. This approach is based on the in vivo production of T cell-engagers (TCE) by engineered cells, which results in effective serum concentrations of TCE, expansion and persistence of adoptively transferred STAb – T cells, and polyclonal recruitment of both modified and unmodified bystander T cells present at the tumor microenvironment. We have validated the therapeutic potential of STAb -T cells  in B-cell and T cell hematological malignancies, and we aim to develop this platform to provide new therapeutic solutions to both hematological and solid tumors.

STAb Therapeutics

Org chart

Teams

Offices

STAb Therapeutics

Org chart

Teams

Offices

Related companies